MYnd Analytics (NASDAQ:MYND) has been given a $18.00 price objective by equities researchers at Maxim Group in a note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 429.41% from the company’s previous close.

The analysts wrote, “Summary Mynd provided a year in review highlighting accomplishments in 2017:.””

Shares of MYnd Analytics (NASDAQ MYND) traded up $0.03 during mid-day trading on Thursday, reaching $3.40. The company had a trading volume of 7,200 shares, compared to its average volume of 9,800. The stock has a market capitalization of $14.41, a PE ratio of -1.34 and a beta of 1.15. MYnd Analytics has a 52 week low of $2.80 and a 52 week high of $9.45.

In other MYnd Analytics news, Director Peter Unanue acquired 15,000 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $3.65 per share, for a total transaction of $54,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 17.81% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “MYnd Analytics (MYND) Given a $18.00 Price Target at Maxim Group” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at

MYnd Analytics Company Profile

MYnd Analytics, Inc, formerly CNS Response, Inc, is a predictive analytics company. The Company has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. The Company provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (PTSD) and other non-psychotic disorders.

Receive News & Ratings for MYnd Analytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYnd Analytics and related companies with's FREE daily email newsletter.